Johnson & Johnson failed to capitalize on the pulsed field ablation wave in the first quarter of 2025, despite recently launching its Varipulse device in the U.S. The healthcare giant on Tuesday ...

Additional information on Johnson & Johnson's data presented at HRS can be found here. The VARIPULSE™ Platform consists of the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 ...

During its quarterly earnings report, executives at Johnson & Johnson said they expect ... after the company’s paused U.S. rollout of its Varipulse pulsed field ablation system, J&J has now ...

Johnson & Johnson and its affiliates 2025 ... the end of the procedure and had a 90% performance goal. iv VARIPURE (VARIPULSE™ Catheter data exchange Platform powered by SECURE) is a SECURE ...

"The VARIPULSE™ Platform has both a strong safety ... 3 These multiplatform findings advance the clinical and technical validation of Johnson & Johnson MedTech's PFA portfolio across focal ...

Omny-IRE data demonstrated the investigational OMNYPULSE™ Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durability at three months, with promising safety outcomes ...